Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration.
Tuberculosis is the oldest of the world's current pandemics and causes 8.9 million new cases and 1.7 million deaths annually. The disease is among the most common causes of morbidity and mortality in people living with HIV. However, tuberculosis is more than just part of the global HIV problem; well-resourced tuberculosis programmes are an important part of the solution to scaling-up towards universal access to comprehensive HIV prevention, diagnosis, care, and support. This article reviews the impact of the interactions between tuberculosis and HIV in resource-limited settings; outlines the recommended programmatic and clinical responses to the dual epidemics, highlighting the role of tuberculosis/HIV collaboration in increasing access to prevention, diagnostic, and treatment services; and reviews progress in the global response to the epidemic of HIV-related tuberculosis.
Reid
Alasdair
A
Stop TB Department, WHO, Geneva, Switzerland.
Scano
Fabio
F
Getahun
Haileyesus
H
Williams
Brian
B
Dye
Christopher
C
Nunn
Paul
P
De Cock
Kevin M
KM
Hankins
Catherine
C
Miller
Bess
B
Castro
Kenneth G
KG
Raviglione
Mario C
MC
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004196:Disease Outbreaks; D014943:Global Health; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D006297:Health Services Accessibility; D006801:Humans; D015995:Prevalence; D016896:Treatment Outcome; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D018088:Tuberculosis, Multidrug-Resistant / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control
D019380:Anti-HIV Agents